Roche will present new data from its Alzheimer’s development portfolio at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada, from July 27 to 30. These results demonstrate Roche’s all-encompassing approach to treating Alzheimer’s disease at every stage of the patient journey.
Key presentations highlight results from the Phase Ib/IIa Brainshuttle™ AD study, demonstrating continued support for rapid and strong amyloid plaque reduction. The design of the next Phase III TRONTIER 1 and 2 trials for experimental trontinemab in Alzheimer’s disease with early symptoms was also discussed. Roche also revealed plans for a new Phase III trial of trontinemab in preclinical Alzheimer’s, targeting individuals at risk, to explore delaying or preventing disease progression.
